Alternative donor transplant of benign primary hematologic disorders.

abstract：:High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid tumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting. To determine the implications of nephrotoxicity on hematological recovery and clinical outcome, we analyzed...

journal_title：Bone marrow transplantation

authors： Beyer J,Rick O,Weinknecht S,Kingreen D,Lenz K,Siegert W

更新日期：1997-11-01 00:00:00

abstract：:Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...

journal_title：Bone marrow transplantation

authors： Giné E,Rovira M,Real I,Burrel M,Montaña J,Carreras E,Montserrat E

更新日期：2003-05-01 00:00:00

abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

journal_title：Bone marrow transplantation

authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

更新日期：2018-09-01 00:00:00

abstract：:Thirty-five patients with myelodysplastic syndromes (MDS) were treated with BMT between 1986 and 1994. Their median age was 41 years (range 23-60). Thirteen patients had transfusion-dependent refractory anaemia (RA). Twenty-two patients suffered from more advanced stages of MDS, 15 being in complete remission (CR) aft...

journal_title：Bone marrow transplantation

authors： Mattijssen V,Schattenberg A,Schaap N,Preijers F,De Witte T

更新日期：1997-04-01 00:00:00

abstract：:Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

journal_title：Bone marrow transplantation

authors： Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

更新日期：2000-05-01 00:00:00

abstract：:We report a patient with CML who developed a reversible dilated cardiomyopathy with cardiac failure following 10 months of IFN therapy. Despite the previous cardiomyopathy, he tolerated subsequent allogeneic BMT without any adverse cardiac events. Reversible IFN-induced cardiomyopathy should not be considered a contra...

journal_title：Bone marrow transplantation

authors： Broady R,Hawkins T,Browett P,Palmer S

更新日期：1998-04-01 00:00:00

abstract：:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

journal_title：Bone marrow transplantation

authors： Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

更新日期：2012-02-01 00:00:00

abstract：:High-dose cyclophosphamide (HD-CY; 7 g/m2) was administered to patients suffering from high risk multiple myeloma (MM). The safety of this procedure, the recirculation and collection of peripheral blood stem cells (PBSC) and the effect of rhGM-CSF and HD-CY were studied. Group I patients (n = 21) were treated with HD-...

journal_title：Bone marrow transplantation

authors： Boiron JM,Marit G,Fabéres C,Cony-Makhoul P,Foures C,Ferrer AM,Cristol G,Sarrat A,Girault D,Reiffers J

更新日期：1993-07-01 00:00:00

abstract：:Six children with clinical and hematologic features of juvenile chronic myelogenous leukemia (JCML) underwent bone marrow transplantation (BMT) using T cell-depleted marrow from non-HLA-matched related or closely HLA-matched unrelated donors. Patient ages ranged from 1.2 to 5 years. Four patients received cytoreductiv...

journal_title：Bone marrow transplantation

authors： Bunin NJ,Casper JT,Lawton C,Murray K,Camitta BM,Greenwood M,Geil J,Ash RC

更新日期：1992-02-01 00:00:00

abstract：:Multiple clinical studies have been undertaken to evaluate the role of ABMT in relapse, in second and subsequent remission (CR greater than or equal to 2), and in first remission (CR1). The value of these high dose cytoreductive programs with ABMT is not yet known. No randomized studies have been done yet indicating t...

journal_title：Bone marrow transplantation

authors： Dicke KA,Spinolo JA

更新日期：1989-01-01 00:00:00

abstract：:With the increasing use and success of BMT, larger numbers of children survive transplantation. Still, cancer treatment in children causes damage to the endocrine glands, often inducing growth deficiency, pubertal delay and thyroid dysfunction. This paper will deal with some of the most common endocrine disorders rela...

journal_title：Bone marrow transplantation

authors： Cohen A,Rovelli R,Zecca S,Van-Lint MT,Parodi L,Grasso L,Uderzo C

更新日期：1998-04-01 00:00:00

abstract：:Diarrhea in marrow transplant recipients is a frequent complication attributable to non-infectious events such as acute GVHD or infectious events such as viral gastroenteritis. Rotavirus and enteric adenovirus are the most frequent viral pathogens. To determine the frequency of these infections, we prospectively exami...

journal_title：Bone marrow transplantation

authors： Troussard X,Bauduer F,Gallet E,Freymuth F,Boutard P,Ballet JJ,Reman O,Leporrier M

更新日期：1993-12-01 00:00:00

abstract：:Patients undergoing bone marrow transplantation are profoundly immunosuppressed as a result of their intensive myeloablative chemotherapy and are at high risk for opportunistic fungal infections mainly caused by Candida spp and Aspergillus spp. Trichosporon beigelii (T beigelii) has emerged as a life-threatening oppor...

journal_title：Bone marrow transplantation

authors： Erer B,Galimberti M,Lucarelli G,Giardini C,Polchi P,Baronciani D,Gaziev D,Angelucci E,Izzi G

更新日期：2000-04-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

journal_title：Bone marrow transplantation

authors： Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

更新日期：2013-01-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

journal_title：Bone marrow transplantation

authors： Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

更新日期：2020-05-01 00:00:00

abstract：:Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34(+) cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 10(6) CD34(+) ...

journal_title：Bone marrow transplantation

authors： Chen AI,Bains T,Murray S,Knight R,Shoop K,Bubalo J,Fowler C,Slater S,Maziarz RT

更新日期：2012-12-01 00:00:00

abstract：:Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St Jude Children's Research Hospital between November 1990 and December 1994 identified 6% (seven male, six female) with adenovirus infection. The affected patients had a median age of 7.9 years (range 3-24 years) at tim...

journal_title：Bone marrow transplantation

authors： Hale GA,Heslop HE,Krance RA,Brenner MA,Jayawardene D,Srivastava DK,Patrick CC

更新日期：1999-02-01 00:00:00

abstract：:Fentanyl is a synthetic opioid that can be delivered through a transdermal therapeutic system (TTS). The aim of this study was to assess the efficacy of fentanyl TTS in treating oral mucositis pain in 75 adult hematopoietic stem cell transplant (HSCT) patients. The analysis was based on 62 patients who developed mucos...

journal_title：Bone marrow transplantation

authors： Demarosi F,Lodi G,Soligo D,Sardella A,Volpe AD,Carrassi A,Deliliers GL

更新日期：2004-06-01 00:00:00

abstract：:Allogeneic SCT remains the only potential cure for patients with thalassemia. However, most BMT candidates lack a suitable family donor and require an unrelated donor (UD). We evaluated whether BMT using UDs in high-risk adult thalassemia patients can offer a probability of cure comparable to that reported employing a...

journal_title：Bone marrow transplantation

authors： La Nasa G,Caocci G,Argiolu F,Giardini C,Locatelli F,Vacca A,Orofino MG,Piras E,Addari MC,Ledda A,Contu L

更新日期：2005-12-01 00:00:00

abstract：:Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, ...

journal_title：Bone marrow transplantation

authors： Burt RK,Patel D,Thomas J,Yeager A,Traynor A,Heipe F,Arnold R,Marmont A,Collier D,Glatstein E,Snowden J

更新日期：2004-11-01 00:00:00

abstract：:The CD34 antigen is expressed by human hematopoietic progenitor and stem cells. These cells are capable of reconstituting marrow function after marrow-ablative chemo-radiotherapy. Several different technologies have been developed for the separation of CD34+ cells from bone marrow or peripheral blood stem cell (PBSC) ...

journal_title：Bone marrow transplantation

authors： Rowley SD,Loken M,Radich J,Kunkle LA,Mills BJ,Gooley T,Holmberg L,McSweeney P,Beach K,MacLeod B,Appelbaum F,Bensinger WI

更新日期：1998-06-01 00:00:00

abstract：:Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative for patients who need a transplant without having conventional donors. One hundred and five consecutive patients with hematologic malignancies who underwent G-CSF-primed peripheral blood haplo-HSCT without in vitro T-cell depletion i...

journal_title：Bone marrow transplantation

authors： Lin X,Lu ZG,Song CY,Huang YX,Guo KY,Deng L,Tu SF,He YZ,Xu JH,Long H,Wu BY

更新日期：2015-08-01 00:00:00

abstract：:Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

journal_title：Bone marrow transplantation

authors： D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

更新日期：2001-09-01 00:00:00

abstract：:Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at...

journal_title：Bone marrow transplantation

authors： Moscardó F,Sanz GF,de La Rubia J,Jiménez C,Saavedra S,Regadera A,Andreu R,García I,Plumé G,Martínez J,Martín G,Jarque I,Sanz MA

更新日期：2001-05-01 00:00:00

abstract：:Ataxia telangiectasia is a genetic instability syndrome characterized by neurodegeneration, immunodeficiency, severe bronchial complications, hypersensitivity to radiotherapy and an elevated risk of malignancies. Repopulation with ATM-competent bone marrow-derived cells (BMDCs) significantly prolonged the lifespan and...

journal_title：Bone marrow transplantation

authors： Pietzner J,Merscher BM,Baer PC,Duecker RP,Eickmeier O,Fußbroich D,Bader P,Del Turco D,Henschler R,Zielen S,Schubert R

更新日期：2016-04-01 00:00:00

abstract：:Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

journal_title：Bone marrow transplantation

authors： Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

更新日期：2014-05-01 00:00:00

abstract：:Graft rejection has been a problem after bone marrow transplantation for patients with severe aplastic anemia (SAA). Ten children with SAA were conditioned for bone marrow transplantation from HLA-identical siblings, using cyclophosphamide (CY, 50 mg/kg) plus antithymocyte globulin (ATG, 15 mg/kg) for 4 successive day...

journal_title：Bone marrow transplantation

authors： Azuma E,Kojima S,Kato K,Matsuyama T,Yamada Y,Kondo N,Sawada H,Hanada M,Shibata T,Tabata N,Watanabe M,Shimono Y,Deguchi T,Umemoto M,Higashikawa M,Kawasaki H,Komada Y,Sakurai M

更新日期：1997-06-01 00:00:00

abstract：:Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospita...

journal_title：Bone marrow transplantation

authors： Narimatsu H,Kami M,Hara S,Matsumura T,Miyakoshi S,Kusumi E,Kakugawa Y,Kishi Y,Murashige N,Yuji K,Masuoka K,Yoneyama A,Wake A,Morinaga S,Kanda Y,Taniguchi S

更新日期：2005-09-01 00:00:00

abstract：:Aspergillus infections in the pediatric bone marrow transplant (BMT) patients are usually fatal. We began the use of a prophylactic nasal spray of amphotericin in 1990. This nasal spray was provided in addition to low-dose intravenous amphotericin. During the time of this study, the number of fatal cases of aspergillu...

journal_title：Bone marrow transplantation

authors： Trigg ME,Morgan D,Burns TL,Kook H,Rumelhart SL,Holida MD,Giller RH

更新日期：1997-01-01 00:00:00

abstract：:Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

journal_title：Bone marrow transplantation

authors： Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

更新日期：2000-03-01 00:00:00